Sand Hill Global Advisors LLC Sells 2,303 Shares of Johnson & Johnson $JNJ

Key Points

• Sand Hill Global Advisors LLC has reduced its stake in Johnson & Johnson by 4.4%, now holding 49,890 shares valued at approximately $8.27 million.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding estimates and showing a revenue increase of 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30 per share, with a dividend yield of 2.9%, payable on September 9th to shareholders recorded on August 26th.

Sand Hill Global Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,890 shares of the company's stock after selling 2,303 shares during the period. Sand Hill Global Advisors LLC's holdings in Johnson & Johnson were worth $8,274,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Nuveen LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $1,369,188,000. GAMMA Investing LLC lifted its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after acquiring an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Guggenheim reiterated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Citigroup increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Up 0.2%

Shares of Johnson & Johnson stock traded up $0.2860 during midday trading on Friday, reaching $179.2160. 5,090,175 shares of the company's stock traded hands, compared to its average volume of 9,018,164. The company has a market cap of $431.61 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. The company's 50 day simple moving average is $163.04 and its 200 day simple moving average is $159.05. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.